Research & Development

Study Identifies New Signaling Axis in Nervous System Tumors
Research & Development Study Identifies New Signaling Axis in Nervous System Tumors

The most formidable barrier to treating aggressive brain cancer may not be the physical skull or the blood-brain barrier, but the cellular invisibility cloak that allows these tumors to ignore the body’s natural defenses. For decades, the primary strategy in oncology has been to train the immune

How Is Shared Decision-Making Managed in Palliative Cancer Care?
Research & Development How Is Shared Decision-Making Managed in Palliative Cancer Care?

The transition from curative efforts to palliative management represents one of the most emotionally charged and ethically complex phases in modern oncology. Patients facing an incurable diagnosis no longer view medical interventions solely through the lens of survival statistics but rather through

Is Noble’s Hospital Safe After Serious Safety Allegations?
Research & Development Is Noble’s Hospital Safe After Serious Safety Allegations?

The integrity of healthcare systems often rests upon the invisible foundation of public trust, yet recent unsettling reports regarding Noble’s Hospital have forced a sudden and uncomfortable reevaluation of patient safety standards on the Isle of Man. Startling claims circulating through social

Metabolic Enzymes in the Nucleus Redefine Cell Biology
Research & Development Metabolic Enzymes in the Nucleus Redefine Cell Biology

Ivan Kairatov is a leading biopharma expert whose career has been defined by bridging the gap between fundamental molecular research and clinical innovation. With extensive experience in research and development, he has spent years investigating how cellular mechanics can be harnessed to treat

CAR-Astrocyte Cellular Immunotherapy – Review
Research & Development CAR-Astrocyte Cellular Immunotherapy – Review

The human brain possesses an intricate waste-clearance system that, when functioning correctly, prevents the toxic buildup of proteins associated with cognitive decline. However, for millions of individuals, this biological janitorial service fails, leading to the relentless progression of

Roche and Zealand Obesity Drug Fails to Impress Investors
Research & Development Roche and Zealand Obesity Drug Fails to Impress Investors

The pharmaceutical industry is currently witnessing a gold rush of unprecedented proportions as global giants race to claim dominance in the multi-billion-dollar obesity treatment sector. This week, the spotlight turned toward the highly anticipated Phase 2 results of petrelintide, a drug developed

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later